Fabry disease cannot be prevented in someone who has already inherited the gene mutation that causes it. It is a genetic condition passed through the X chromosome, and no lifestyle change or medication can stop it from developing in a person born with the faulty gene. However, there are effective ways to prevent passing the mutation to the next generation, and early treatment can prevent much of the serious organ damage the disease is known for.
How Fabry Disease Is Inherited
Fabry disease is caused by a mutation in the GLA gene, which sits on the X chromosome. Because the inheritance is X-linked, the odds of passing it on depend entirely on which parent carries the mutation and the sex of the child.
If the father has Fabry disease, he will pass the mutated X chromosome to every one of his daughters, making them all carriers (and often symptomatic to varying degrees). He cannot pass it to his sons, because sons receive his Y chromosome instead. If the mother carries the mutation, each pregnancy has a 50% chance of passing the faulty gene along, regardless of whether the child is a boy or a girl. A son who inherits it will typically develop the classic, more severe form. A daughter who inherits it becomes a carrier and may experience a wide range of symptoms due to random X-chromosome inactivation.
Preventing Transmission to Children
For people who know they carry a GLA mutation, the most direct way to prevent Fabry disease in the next generation is through assisted reproduction. During IVF, a technique called preimplantation genetic testing for monogenic disease (PGT-M) can identify which embryos carry the mutation before a pregnancy even begins. A small number of cells are removed from each embryo, typically around day five to seven of development, and tested using genetic markers. Only embryos confirmed to be free of the mutation are transferred.
This approach reduces the chance of having an affected child by more than 95%, with reported misdiagnosis rates below 1%. In one large laboratory review, 73% of cases that underwent PGT-M had at least one unaffected, chromosomally normal embryo available for transfer. It is not a guarantee, but it is the closest thing to prevention that currently exists for a purely genetic disease.
Prenatal Testing During Pregnancy
If conception has already occurred naturally, prenatal diagnosis can determine whether the fetus carries the mutation. Chorionic villus sampling (CVS) can be performed as early as 10 weeks of pregnancy by taking a small sample of placental tissue. Amniocentesis is another option, typically done around 16 weeks by extracting a small amount of amniotic fluid. Both provide fetal cells suitable for genetic analysis. These tests don’t prevent the disease, but they give families time to prepare and plan for early treatment if the mutation is present.
Catching It Early Through Screening
When Fabry disease is diagnosed late, patients often already have irreversible kidney damage, heart problems, or stroke. Early detection is itself a form of prevention, not of the disease, but of the damage it causes. Two screening strategies are gaining traction.
Cascade screening is the most productive approach currently available. Once one person in a family is diagnosed, genetic testing fans outward through three generations. The process follows the X-linked inheritance pattern: if the diagnosed person is male, his mother, daughters, and siblings are tested first. If female, both parents and all children are tested, then siblings depending on which parent carries the variant. Each time a new carrier is found, the cycle repeats. A 20-year program at the Danish Fabry Disease Centre demonstrated how systematically this can uncover undiagnosed relatives who are already accumulating organ damage without knowing it.
Newborn screening for Fabry disease has been piloted in several countries but has not yet been adopted as standard newborn care anywhere. It remains an area of active discussion, since identifying the disease at birth would allow monitoring from infancy and treatment at the earliest possible stage.
Preventing Organ Damage With Treatment
For someone already living with Fabry disease, the most important preventive action is starting treatment before organs are significantly damaged. The disease works by allowing a fatty substance called globotriaosylceramide to build up in cells throughout the body, gradually injuring the kidneys, heart, and nervous system. Treatment clears or reduces this buildup.
Enzyme replacement therapy (ERT) delivers a manufactured version of the enzyme that Fabry patients lack. A Korean study following 19 patients over an average of eight years found that kidney function declined at a slower rate than expected, especially in patients who had lower levels of protein in their urine before starting treatment. Heart wall thickness either decreased or held steady. In female carriers and children who began treatment early, both kidney and heart function remained stable throughout the study period. The key finding: patients who already had irreversible organ damage saw limited benefit, while those treated earlier fared significantly better.
For a subset of patients whose specific mutation produces a misfolded but partially functional enzyme, an oral chaperone therapy called migalastat is an option. The drug works by binding to the misshapen enzyme inside cells, helping it fold correctly so it can reach the part of the cell where it is needed. Not every mutation responds to this treatment. A mutation is considered “amenable” if it meets specific laboratory thresholds showing the enzyme’s activity meaningfully increases in the drug’s presence. One notable advantage of this approach over infused enzyme therapy is that the small molecule can cross the blood-brain barrier, potentially addressing neurological symptoms that infusions cannot reach.
Protecting the Kidneys
Beyond disease-specific therapy, blood pressure medications that reduce protein leakage in the kidneys play an important supporting role. A study of patients with classic Fabry disease found that those who kept their urine protein levels at or below a specific threshold while on enzyme therapy maintained better kidney function over time. Starting enzyme therapy at a younger age also correlated with better kidney preservation. For most Fabry patients, managing blood pressure and protein leakage is a standard part of the treatment plan alongside enzyme therapy.
Gene Therapy as a Potential One-Time Fix
A Canadian clinical trial recently published five-year results from a gene therapy approach in which patients’ own blood cells were modified to produce the missing enzyme, then infused back. All five patients began producing the enzyme within days of treatment, and that production remained durable for more than five years. Four of five patients saw significant reductions in a key biomarker of disease activity, and kidney symptoms stabilized in all five. Three of the five patients were able to stop their regular enzyme infusions entirely. No adverse events related to the gene therapy itself occurred during the entire follow-up period. The trial was small, but the durability of the results suggests this could eventually offer a one-time treatment that removes the need for lifelong infusions.